224 related articles for article (PubMed ID: 23670732)
1. [Monoclonal gammopathy of undetermined significance and monoclonal B-lymphocytosis].
Hübel K; Hallek M
Internist (Berl); 2013 Jun; 54(6):709-14. PubMed ID: 23670732
[TBL] [Abstract][Full Text] [Related]
2. Patient and provider-level drivers of healthcare utilization related to a diagnosis of a precancerous condition: monoclonal gammopathy of undetermined significance (MGUS).
Castañeda-Avila MA; Mazor KM; Lapane KL; Epstein MM
Cancer Causes Control; 2023 May; 34(5):449-457. PubMed ID: 36853428
[TBL] [Abstract][Full Text] [Related]
3. Diagnosis, risk stratification and management of monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
van de Donk NW; Mutis T; Poddighe PJ; Lokhorst HM; Zweegman S
Int J Lab Hematol; 2016 May; 38 Suppl 1():110-22. PubMed ID: 27161311
[TBL] [Abstract][Full Text] [Related]
4. Hospital population screening reveals overrepresentation of CD5(-) monoclonal B-cell lymphocytosis and monoclonal gammopathy of undetermined significance of IgM type.
Voigtlaender M; Vogler B; Trepel M; Panse J; Jung R; Bokemeyer C; Bacher U; Binder M
Ann Hematol; 2015 Sep; 94(9):1559-65. PubMed ID: 26040471
[TBL] [Abstract][Full Text] [Related]
5. Monoclonal Gammopathy of Undetermined Significance After Kidney Transplantation: Single-Center Experience.
Alfano G; Fontana F; Colaci E; Messerotti A; Bettelli F; Potenza L; Luppi M; Cappelli G
Transplantation; 2017 Nov; 101(11):e337-e342. PubMed ID: 28731904
[TBL] [Abstract][Full Text] [Related]
6. Molecular and biologic markers of progression in monoclonal gammopathy of undetermined significance to multiple myeloma.
Mailankody S; Mena E; Yuan CM; Balakumaran A; Kuehl WM; Landgren O
Leuk Lymphoma; 2010 Dec; 51(12):2159-70. PubMed ID: 20958231
[TBL] [Abstract][Full Text] [Related]
7. Monoclonal B-cell lymphocytosis, monoclonal gammopathy of undetermined significance, and T-cell clones of uncertain significance: are these premalignant conditions sharing a common identity?
Semenzato G; Ghobrial IM; Ghia P
Lancet Haematol; 2023 Jul; 10(7):e549-e556. PubMed ID: 37407144
[TBL] [Abstract][Full Text] [Related]
8. Monoclonal Gammopathy of Undetermined Significance: A Comprehensive Review.
Kaur J; Valisekka SS; Hameed M; Bandi PS; Varma S; Onwughalu CJ; Ibrahim H; Mongia H
Clin Lymphoma Myeloma Leuk; 2023 May; 23(5):e195-e212. PubMed ID: 36966041
[TBL] [Abstract][Full Text] [Related]
9. The Role of Diagnosis and Clinical Follow-up of Monoclonal Gammopathy of Undetermined Significance on Survival in Multiple Myeloma.
Sigurdardottir EE; Turesson I; Lund SH; Lindqvist EK; Mailankody S; Korde N; Björkholm M; Landgren O; Kristinsson SY
JAMA Oncol; 2015 May; 1(2):168-74. PubMed ID: 26181017
[TBL] [Abstract][Full Text] [Related]
10. Prevalence, clinical aspects, and natural history of IgM MGUS.
McMaster ML; Landgren O
Cytometry B Clin Cytom; 2010; 78 Suppl 1(Suppl 1):S91-7. PubMed ID: 20839342
[TBL] [Abstract][Full Text] [Related]
11. Monoclonal Gammopathy of Undetermined Significance (MGUS)Monoclonal Gammopathy of Undetermined Significance (MGUS).
Viera S; Ludek P; Zdeněk A; Marta K; Martin Š; Sabina Š; Zdeněk K
Klin Onkol; 2018; 31(4):270-276. PubMed ID: 30541309
[TBL] [Abstract][Full Text] [Related]
12. Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120).
Dhodapkar MV; Sexton R; Waheed S; Usmani S; Papanikolaou X; Nair B; Petty N; Shaughnessy JD; Hoering A; Crowley J; Orlowski RZ; Barlogie B
Blood; 2014 Jan; 123(1):78-85. PubMed ID: 24144643
[TBL] [Abstract][Full Text] [Related]
13. Diagnosis and Management of Monoclonal Gammopathy and Smoldering Multiple Myeloma.
Schmidt T; Callander N
J Natl Compr Canc Netw; 2020 Dec; 18(12):1720-1729. PubMed ID: 33347744
[TBL] [Abstract][Full Text] [Related]
14. Health impact of monoclonal gammopathy of undetermined significance (MGUS) and monoclonal B-cell lymphocytosis (MBL): findings from a UK population-based cohort.
Lamb MJ; Smith A; Painter D; Kane E; Bagguley T; Newton R; Howell D; Cook G; de Tute R; Rawstron A; Patmore R; Roman E
BMJ Open; 2021 Feb; 11(2):e041296. PubMed ID: 33619185
[TBL] [Abstract][Full Text] [Related]
15. Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma in Older Adults.
Guerard EJ; Tuchman SA
Clin Geriatr Med; 2016 Feb; 32(1):191-205. PubMed ID: 26614868
[TBL] [Abstract][Full Text] [Related]
16. Monoclonal gammopathy of undetermined significance: why identification of these patients and assessment of their skeletons is important.
Berenson JR; Yellin O
Clin Lymphoma Myeloma; 2009 Aug; 9(4):311-5. PubMed ID: 19717382
[TBL] [Abstract][Full Text] [Related]
17. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
Kyle RA
Eur J Haematol Suppl; 1989; 51():70-5. PubMed ID: 2516809
[TBL] [Abstract][Full Text] [Related]
18. Monoclonal Gammopathy of Undetermined Significance: Current Concepts and Future Prospects.
Seth S; Zanwar S; Vu L; Kapoor P
Curr Hematol Malig Rep; 2020 Apr; 15(2):45-55. PubMed ID: 32222885
[TBL] [Abstract][Full Text] [Related]
19. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: a review of the current understanding of epidemiology, biology, risk stratification, and management of myeloma precursor disease.
Agarwal A; Ghobrial IM
Clin Cancer Res; 2013 Mar; 19(5):985-94. PubMed ID: 23224402
[TBL] [Abstract][Full Text] [Related]
20. Computational Model of Progression to Multiple Myeloma Identifies Optimum Screening Strategies.
Altrock PM; Ferlic J; Galla T; Tomasson MH; Michor F
JCO Clin Cancer Inform; 2018 Dec; 2():1-12. PubMed ID: 30652561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
